搜尋結果
尿液有這些異狀快就醫 部桃：嚴重恐洗腎
日前一名傅先生因身體不適在家中暈倒，由太太緊急送至衛生福利部桃園醫院後，診斷出他患有高血糖、高血壓及蛋白尿，並且腎功能已進入第五期的末期腎臟病。 部桃提到，據傅太太表示，2至3年前她注意到先生解尿後尿中有大量泡泡，且周圍聚集許多螞蟻，便感覺事有蹊蹺，勸先生就醫檢查，但先生認為自己身體無
桃園電子報 via Yahoo奇摩新聞
4 天前
台灣洗腎人口快破10萬大關！醫示警初期無症狀「5大問題」快就醫
台灣被喻為「洗腎王國」，洗腎人數超過9萬，人口占比位居全球之冠。但不少民眾仍對腎病一知半解，腎臟科醫師提醒，慢性腎臟病第三期前常無症狀，若出現蛋白尿、血尿等情況應就醫檢查，建議民眾應定期接受健檢，才能及早介入治療、遠離洗腎。（記者：簡浩正）
三立新聞網
17 小時前
3 天前 · Volnea (desogestrel and ethinyl estradiol kit) tablets are a combined oral contraceptive (COC) indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. What Are Side Effects of Volnea? Side effects of Volnea include: nausea, vomiting,
- Mechanism of Action
- Pharmacodynamics
- Pharmacokinetics
- Deficiency of IL-1 Receptor Antagonist
- Recurrent Pericarditis
Rilonacept is an interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β and prevents its interaction with cell surface receptors. Rilonacept also binds interleukin-1 receptor antagonist (IL-1ra). The equilibrium dissociation con...
C-Reactive Protein (CRP) and Serum Amyloid A (SAA) are indicators of inflammatory disease activity that are elevated in patients with CAPS. Elevated SAA has been associated with the development of systemic amyloidosisin patients with CAPS. Compared to placebo, treatment with ARCALYST resulted in sustained reductions from baseline in mean serum CRP ...
The average trough levels of rilonacept were approximately 24 mcg/mL at steady state following weekly subcutaneous doses of 160 mg for up to 48 weeks in patients with CAPS. The steady state appeared to be reached by 6 weeks. The average trough levels of rilonacept were approximately 23 mcg/mL at steady state, and the circulationhalf-life in vivo wa...
The safety and efficacy of ARCALYST for the maintenance of remission of DIRA were demonstrated in a 2-year, open-label study (NCT01801449) of 6 pediatric patients who previously experienced clinical benefit from daily injections of an IL-1 receptor antagonist, anakinra. The study populationincluded patients with a loss-of-function IL1RN mutations. ...
The efficacy and safety of ARCALYST were evaluated in the Phase 3 study RHAPSODY (NCT03737110), a double-blind, placebo-controlled, randomized withdrawal, multinational study. The study consisted of a 12-week run-in followed by a double-blind, placebo-controlled, randomized withdrawal period. In the run-in period, adult patients received a loading ...
